These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36596264)

  • 21. Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis.
    Alfayez OM; Almohammed OA; Alkhezi OS; Almutairi AR; Al Yami MS
    Cardiovasc Diabetol; 2020 Jun; 19(1):96. PubMed ID: 32571416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular outcome trials and major cardiovascular events: does glucose matter? A systematic review with meta-analysis.
    Giugliano D; Chiodini P; Maiorino MI; Bellastella G; Esposito K
    J Endocrinol Invest; 2019 Oct; 42(10):1165-1169. PubMed ID: 30955180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Initiating a GLP1 Agonist and/or SGLT2 Inhibitor Therapy on De-Escalation and Discontinuation of Insulin and Diabetes Control When Managed by an Interprofessional Collaborative Team.
    Champion M; Wills Avila G; Garcia AE; Álvarez Delgado FM; Valdez CA
    J Prim Care Community Health; 2024; 15():21501319241231398. PubMed ID: 38353180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials.
    Kapoor I; Sarvepalli SM; D'Alessio D; Grewal DS; Hadziahmetovic M
    Surv Ophthalmol; 2023; 68(6):1071-1083. PubMed ID: 37454782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta-analysis of randomized placebo-controlled outcome trials.
    Ferreira JP; Saraiva F; Sharma A; Vasques-Nóvoa F; Angélico-Gonçalves A; Leite AR; Borges-Canha M; Carvalho D; Packer M; Zannad F; Leite-Moreira A; Neves JS
    Diabetes Obes Metab; 2023 Jun; 25(6):1495-1502. PubMed ID: 36722252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes.
    Gorgojo-Martínez JJ; Serrano-Moreno C; Sanz-Velasco A; Feo-Ortega G; Almodóvar-Ruiz F
    Nutr Metab Cardiovasc Dis; 2017 Feb; 27(2):129-137. PubMed ID: 28077257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice.
    Fu EL; Clase CM; Janse RJ; Lindholm B; Dekker FW; Jardine MJ; Carrero JJ
    Int J Cardiol; 2022 Apr; 352():172-179. PubMed ID: 35074492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy.
    Vilsbøll T; Bain SC; Leiter LA; Lingvay I; Matthews D; Simó R; Helmark IC; Wijayasinghe N; Larsen M
    Diabetes Obes Metab; 2018 Apr; 20(4):889-897. PubMed ID: 29178519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
    Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
    J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
    [No Abstract]   [Full Text] [Related]  

  • 30. Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis.
    Andreadis P; Karagiannis T; Malandris K; Avgerinos I; Liakos A; Manolopoulos A; Bekiari E; Matthews DR; Tsapas A
    Diabetes Obes Metab; 2018 Sep; 20(9):2255-2263. PubMed ID: 29756388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes.
    Tuchscherer RM; Thompson AM; Trujillo JM
    Ann Pharmacother; 2018 Dec; 52(12):1224-1232. PubMed ID: 29932006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
    Urquhart S; Willis S
    JAAPA; 2020 Aug; 33(8):19-30. PubMed ID: 32740122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
    Cowart K
    Ann Pharmacother; 2020 May; 54(5):478-485. PubMed ID: 31744308
    [No Abstract]   [Full Text] [Related]  

  • 34. Glucagon-like peptide-1 (GLP-1) receptor agonists in type 2 diabetes and long-term complications: FOCUS on retinopathy.
    Marchand L; Luyton C; Bernard A
    Diabet Med; 2021 Jan; 38(1):e14390. PubMed ID: 32799379
    [No Abstract]   [Full Text] [Related]  

  • 35. HbA
    Bethel MA; Diaz R; Castellana N; Bhattacharya I; Gerstein HC; Lakshmanan MC
    Diabetes Care; 2021 Jan; 44(1):290-296. PubMed ID: 33444163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral versus subcutaneous semaglutide for prevention of major adverse cardiovascular events: cost per outcome analysis of SUSTAIN-6 and PIONEER-6.
    Hammerman A; Moore CM; Aboalhasan E; Azuri J; Arbel R
    Postgrad Med; 2022 Sep; 134(7):654-658. PubMed ID: 35701876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.
    Monami M; Nreu B; Scatena A; Cresci B; Andreozzi F; Sesti G; Mannucci E
    Diabetes Obes Metab; 2017 Sep; 19(9):1233-1241. PubMed ID: 28244632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist.
    Bucheit JD; Pamulapati LG; Carter N; Malloy K; Dixon DL; Sisson EM
    Diabetes Technol Ther; 2020 Jan; 22(1):10-18. PubMed ID: 31436480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral semaglutide - Rybelsus®, the first GLP-1 receptor agonist for oral use in clinical practice.
    Karásek D
    Vnitr Lek; 2022; 68(2):89-95. PubMed ID: 36208922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of injectable semaglutide for type 2 diabetes.
    Peter R; Bain SC
    Expert Opin Drug Saf; 2020 Jul; 19(7):785-798. PubMed ID: 32428416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.